A5036153462- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Cancer-related cognitive impairment studies
- Prostate Cancer Treatment and Research
- Cancer survivorship and care
- Cancer, Lipids, and Metabolism
Karolinska University Hospital
2021-2024
Karolinska Institutet
2016-2024
PURPOSE To assess the long-term (20-year) endocrine therapy benefit in premenopausal patients with breast cancer. METHODS Secondary analysis of Stockholm trial (STO-5, 1990-1997) randomly assigning 924 to 2 years goserelin (3.6 mg subcutaneously once every 28 days), tamoxifen (40 orally daily), combined and tamoxifen, or no adjuvant (control) is performed. Random assignment was stratified by lymph node status; node–positive (n = 459) were allocated standard chemotherapy (cyclophosphamide,...
Literature focusing on health-related quality of life (HRQoL) by cancer site among women only is scarce. This study examines HRQoL breast (BC) survivors compared with female other cancers, and to understand which subgroups BC were particularly at risk reduced HRQoL. We placed emphasis young (<50 years) recently diagnosed (≤5 survivors, where the deficits in most pronounced. The cross-sectional consisted 2,224 8,504 non-cancer controls 2,205 Karma study. examined differences using linear...
<h3>Importance</h3> Clinically used breast cancer markers, such as tumor size, grade, progesterone receptor (PR) status, and Ki-67 are known to be associated with short-term survival, but the association of these markers long-term (25-year) survival is unclear. <h3>Objective</h3> To assess clinically treatment benefit among postmenopausal women lymph node–negative, estrogen [ER]–positive and<i>ERBB2</i>-negative who received tamoxifen therapy. <h3>Design, Setting, Participants</h3> This...
Abstract Background Estrogen receptor–positive breast cancer patients have a long-term risk of distant metastatic disease, and premenopausal higher risk. Randomized studies with follow-up are essential to understand treatment benefit. We elucidated the tamoxifen therapy benefit by menopausal status in Stockholm trials 20 years complete follow-up. Methods Secondary analysis 1242 estrogen HER2-negative that were randomly assigned 2-5 40 mg adjuvant or no endocrine therapy. Distant...
Abstract Background: Women with estrogen receptor (ER)-positive disease have a long-term risk of distant recurrence. The poor survival premenopausal women diagnosed breast cancer combined the otherwise long life expectancy makes it especially important to identify tumor characteristics associated survival. Intra-tumor heterogeneity, having cells varying across tumor, may promote therapeutic resistance and metastatic capacity. We previously shown that high intra-tumor heterogeneity ER...
Abstract Background: Tamoxifen is a standard endocrine therapy for both pre- and postmenopausal ER-positive breast cancer patients. Patients with disease have long-term risk of distant recurrence, thus, follow-up studies are essential to understand true treatment benefit. Clinically used tumor characteristics prognostic 5-10 years after primary diagnosis, however, whether these predictive tamoxifen benefit largely unexplored. Therefore, we aimed determine the by clinically in vs patients...
Abstract Background: The risk for patients with estrogen receptor (ER)-positive breast cancer remains stable decades after primary diagnosis, a large proportion of distant metastatic events occurring late. Thus, long-term follow-up studies are essential to understand true treatment benefit. Tamoxifen (TAM) therapy is fundamental endocrine ER-positive cancer. We have previously shown tamoxifen benefit less aggressive tumor characteristics in ER-positive/HER2-negative patients. However, highly...